Compare IRMD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | JANX |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | 166 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 975.7M |
| IPO Year | 2014 | 2021 |
| Metric | IRMD | JANX |
|---|---|---|
| Price | $92.02 | $15.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $116.00 | $47.00 |
| AVG Volume (30 Days) | 109.3K | ★ 721.4K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $83,814,000.00 | $10,000,000.00 |
| Revenue This Year | $12.38 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $106.06 | ★ N/A |
| Revenue Growth | ★ 14.43 | N/A |
| 52 Week Low | $67.84 | $12.12 |
| 52 Week High | $107.90 | $35.34 |
| Indicator | IRMD | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 57.23 |
| Support Level | $90.96 | $13.13 |
| Resistance Level | $97.63 | $16.68 |
| Average True Range (ATR) | 3.10 | 0.63 |
| MACD | -0.50 | -0.01 |
| Stochastic Oscillator | 18.99 | 78.06 |
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.